Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 10121 - 10128 of 12029 results
Privacy Monday - September 22, 2014
September 22, 2014| Blog| Viewpoint
CMS Continues to Struggle with How to Provide High Quality Care to Dual Eligibles
September 21, 2014| Blog| Viewpoint
Employee's LinkedIn Contacts Once Again Become Focus of Trade Secrets Claim
September 19, 2014| Blog| Viewpoint
What’s Happening with Patents at the USPTO? Chief of Staff Byrnes has Answers!
September 19, 2014| Blog| Viewpoint
Department of Justice Criminal Division Will Increase its Review of False Claims Act Cases for Criminal Prosecution
September 19, 2014| Blog| Viewpoint
Daddy Dearest?: Some Considerations Concerning Paid Parental Leave for Fathers in the United States
September 18, 2014| Blog| Viewpoint
Employment Law Summer Recap 2014: Part 4 of 11 - Chris Pratt and Unexpected Surprises in Hollywood and the World of California Employment Law
September 18, 2014| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|